These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22760046)

  • 1. Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
    Tuaillon E; Lozano C; Kuster N; Poinso A; Kania D; Nagot N; Mondain AM; Pageaux GP; Ducos J; Van de Perre P; Reynes J
    J Clin Microbiol; 2012 Sep; 50(9):3096-8. PubMed ID: 22760046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
    Huang AJ; Núñez M
    J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
    Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
    Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
    Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
    AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
    Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):527-533. PubMed ID: 32692112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
    Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
    AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
    Thibault V; Stitou H; Desire N; Valantin MA; Tubiana R; Katlama C
    Antivir Ther; 2011; 16(2):199-205. PubMed ID: 21447869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
    Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
    Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
    Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
    J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
    Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.
    Begré L; Boyd A; Plissonnier ML; Testoni B; Salazar-Vizcaya L; Suter-Riniker F; Scholtès C; Béguelin C; Rockstroh JK; Günthard HF; Calmy A; Cavassini M; Hirsch HH; Schmid P; Bernasconi E; Levrero M; Wandeler G; Zoulim F; Rauch A;
    J Infect Dis; 2024 Oct; 230(4):e954-e963. PubMed ID: 38626170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
    Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
    J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.